FundraiseBase by

EpilepsyGTx

Raised $33M in a Series A round, announced 10 December 2025.

Round

Funds the first-in-human Phase 1/2a trial of EPY201.

Amount: $33M
Stage: Series A
Announced: 10 December 2025
Lead: XGEN Venture
Other investors: British Business Bank, Undisclosed global biopharma company
Use of funds: Funds the first-in-human Phase 1/2a trial of EPY201.
Checked: Amount and date matched across 3 press sources

Company

Develops single-dose gene therapy for focal refractory epilepsy

Based in: United Kingdom
Sector: Health

Sources and links

Sources: EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy - Ne pulse2.com
EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy - Ne news.google.com
EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy - Ne startuprise.co.uk

Just raised?

MediaBoost gets your round in front of the press, future hires and your next investors.

Announce your round with MediaBoost